With other antiemetic agents in adults to prevent delayed nausea and vomiting associated with initial/repeat courses of emetogenic cancer chemotherapy.
Acts as a selective antagonist at substance P/neurokinin 1 (NK1 ) receptors in the brain.
- Decreased nausea and vomiting associated with chemotherapy.
- Augments the antiemetic effects of dexamethasone and 5-HT3 antagonists.
Absorption: Well absorbed following oral administration.
Protein Binding: 99.8%
Metabolism and Excretion: Mostly metabolized, primarily by CYP3A4; one metabolite, C4–pyrrolidine-hydroxylated rolapitant (M19) has antiemetic activity. Excretion is mainly via hepato/biliary elimination. 14% excreted in urine (8% as metabolites), 73% in feces (38% as unchanged drug).
Half-life: Rolapitant– 7 days; M19– 7 days.
TIME/ACTION PROFILE (blood levels)
|PO||within 30 min||4 hr||7 days|
- Concurrent use of thioridazine or pimozide.
Use Cautiously in:
- Concurrent use of other substrates of CYP2D6 with narrow therapeutic indeces (avoid concurrent use if possible, if necessary monitor carefully);
- Severe hepatic impairment (avoid if possible, if unavoidable monitor carefully);
- Severe renal impairment (effect on pharmacokinetics not known;
- Geri: Elderly patients may be more sensitive to drug effects;
- OB: Effects in pregnancy are unknown;
- Lactation:Weigh maternal benefits against risks to the infant;
- Pedi: Safe and effective use in children has not been established.
Adverse Reactions/Side Effects
CV: dizziness (↑ with anthracycline/cyclophosphamide regimens)
GI: ↓ appetite (↑ with anthracycline/cyclophosphamide regimens), hiccups (↑ with cisplatin regimens)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
- ↑ levels and risk of serious cardiac toxicity with thioridazine and pimozide; thioridazine is contraindicated, pimozide should be avoided.
- ↑ levels effects and risk of toxicity from irinotecan , methotrexate , rosuvastatin and topotecan , may have a similar effect on other drugs that are handled by Breast-Cancer-Resistance protein (BCRP) transporter; dose reduction may be necessary.
- ↑ levels, effects and risk of toxicity from digoxin and other drugs that are metabolized by P-glycoprotein (P-gp) transporter, especially those with narrow therapeutic indeces, careful monitoring is recommended.
- Strong CYP3A4 inducers including rifampin ↓ blood levels and effectiveness.
PO: (Adults) 180 mg 1–2 hr prior to start of chemotherapy; with dexamethasone and a 5-HT3 antagonist.
Tablets: 90 mg
- Assess nausea, vomiting, appetite, bowel sounds, and abdominal pain prior to and following administration.
Lab Test Considerations:
May cause ↓ WBC.
- PO: Administer 1–2 hr before chemotherapy without regard to food. Due to long action, administered no more frequently than onceevery 14 days. Given with dexamethasone and a 5-HT3 antagonist.
- Instruct patient to take rolapitant as directed. Direct patient to read the Patient Package Insert before starting therapy and each time Rx renewed in case of changes.
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
- Advise patient and family to use general measures to decrease nausea (begin with sips of liquids and small, nongreasy meals; provide oral hygiene; remove noxious stimuli from environment).
- Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.
Decreased delayed nausea and vomiting associated with emetogenic chemotherapy.
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Learn more.